HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) today announced that further clinical results from the Company’s studies of NX-1207 for benign prostatic hyperplasia (BPH) will be presented at the Mid-Atlantic Section of the American Urological Association Meeting in Bermuda in October. The paper is authored by leading clinical research investigators from U.S. clinical trials of NX-107. Further specific details on the upcoming presentation will be announced at a later date.
